Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.70 |
| ▸ | CTSB | P07858 | 13/20 | 0.69 |
| ▸ | CTSL | P07711 | 8/20 | 0.69 |
| ▸ | CTSK | P43235 | 6/20 | 0.69 |
| ▸ | CTSS | P25774 | 3/20 | 0.69 |
| ▸ | ELANE | P08246 | 2/20 | 0.69 |
| ▸ | CTSV | O60911 | 1/20 | 0.69 |
| ▸ | PLG | P00747 | 1/20 | 0.69 |
| ▸ | CMA1 | P23946 | 1/20 | 0.69 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2324921 | 1.00 | ABCG2 (0.70) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL13058622 | 1.00 | ABCG2 (0.70) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL2324915 | 1.00 | ABCG2 (0.70) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL2324929 | 1.00 | ABCG2 (0.70) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL16474284 | 1.00 | ABCG2 (0.70) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL15086011 | 0.92 | CTSB (0.61) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL13644672 | 0.91 | ABCG2 (0.73) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL15757106 | 0.91 | ABCG2 (0.73) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL13092010 | 0.91 | ABCG2 (0.73) | ABCG2CTSBCTSLCTSKCTSS | |
| SCHEMBL15764305 | 0.91 | ABCG2 (0.73) | ABCG2CTSBCTSLCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107318-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107318-A1 | PROCESSES AND INTERMEDIATES | TFPI, SPINT2, SERPINB1 | ABCG2 2390/4885CTSB 49/4885CTSL 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.